Page 1,316«..1020..1,3151,3161,3171,318..1,3301,340..»

New OPSUMIT (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical and Functional Parameters in Patients with…

Posted: Published on October 23rd, 2019

OPSUMIT, as part of a combination regimen, reduced the primary endpoint of mean pulmonary vascular resistance by 47% at week 16 compared with baseline NEW ORLEANS, Oct. 21, 2019 /PRNewswire/ -- Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, today announces new data evaluating initial combination therapy with OPSUMIT (macitentan) and tadalafIl, a PDE5 inhibitor. Patients with pulmonary arterial hypertension (PAH, WHO Group 1) taking this combination showed hemodynamic improvement, as well as improvements in functional parametersand risk profiles.The combination was also well tolerated in these patients. Continue reading →

Posted in Hypertension | Comments Off on New OPSUMIT (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical and Functional Parameters in Patients with…

Death of Clay County inmate prompts change in housing for inmates with specific medical needs – FirstCoastNews.com WTLV-WJXX

Posted: Published on October 23rd, 2019

GREEN COVE SPRINGS, Fla. Continue reading →

Posted in Hypertension | Comments Off on Death of Clay County inmate prompts change in housing for inmates with specific medical needs – FirstCoastNews.com WTLV-WJXX

Dapagliflozin Receives FDA Approval for Reducing Heart Failure Hospitalization Risk – Endocrinology Advisor

Posted: Published on October 23rd, 2019

Home Topics Diabetes Type 2 Diabetes The Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin; AstraZeneca) to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. The approval was based on data from the DECLARE-TIMI 58 study which evaluated the effect of Farxiga (n=8582) vs placebo (n=8578) on cardiovascular outcomes when added to current background therapy; all patients in the study had type 2 diabetes and either established CVD or 2 or more additional CV risk factors (55 years old in men or 60 years old in women and 1 or more of dyslipidemia, hypertension, or current tobacco use). Results showed that treatment with Farxiga was superior to placebo in reducing the incidence of the primary composite end point of hospitalization for heart failure or CV death (hazard ratio [HR] 0.83 [95% CI: 0.73, 0.95; P =.005]). Continue reading →

Posted in Hypertension | Comments Off on Dapagliflozin Receives FDA Approval for Reducing Heart Failure Hospitalization Risk – Endocrinology Advisor

STN-DBS Leads to Similar Benefits in Men and Women With Parkinson’s, Study Finds – Parkinson’s News Today

Posted: Published on October 23rd, 2019

Apart from physical health-related quality of life which seemed to improve to a greater extent in males the benefits of subthalamic nucleus deep brain stimulation (STN-DBS) on motor, cognitive, and mental function are similar in men and women with Parkinsons disease, a study has found. The study, Sex differences in the short-term and long-term effects of subthalamic nucleus stimulation in Parkinsons disease, was published in Parkinsonism and Related Disorders. STN-DBS is a non-destructive surgical treatment for Parkinsons disease that involves implanting a device to stimulate targeted regions of the brain with electrical impulses generated by a battery-operated neurostimulator. Continue reading →

Posted in Parkinson's Treatment | Comments Off on STN-DBS Leads to Similar Benefits in Men and Women With Parkinson’s, Study Finds – Parkinson’s News Today

What the Heck Is That? – The New York Times

Posted: Published on October 23rd, 2019

The amino acid L-dopa, also known as levodopa, is best known as a treatment for the symptoms of Parkinsons disease. It has appeared in the New York Times Crossword 20 times. Continue reading →

Posted in Parkinson's Treatment | Comments Off on What the Heck Is That? – The New York Times

Feds warn company over unsubstantiated claims that cannabidiol products can treat Parkinson’s, Alzheimer’s – News – McKnight’s Long Term Care News

Posted: Published on October 23rd, 2019

A Florida company that sells products with cannabidiol has been warned for unsubstantiated claims that its products could be used to treat several ailments, including Parkinsons and Alzheimers diseases. The Food and Drug Administration and Federal Trade Commission issued the warning Tuesday in a joint letter to Rooted Apothecary LLC, in Naples, FL. The agency claims the company is illegally selling unapproved products containing CBD and has used its online store and social media sites to make unfounded claims about the products. Continue reading →

Posted in Parkinson's Treatment | Comments Off on Feds warn company over unsubstantiated claims that cannabidiol products can treat Parkinson’s, Alzheimer’s – News – McKnight’s Long Term Care News

Parkinson’s Patients Response to DBS May Depend on Years of Schooling – Parkinson’s News Today

Posted: Published on October 23rd, 2019

The more years of formal education that people with Parkinsons disease have, the better they seem to respond to deep-brain stimulation as seen in a greater ability to dual-task, or engage in higher-level thought while walking, a study suggests. Education level affects dual-task gait after deep brain stimulation in Parkinsons disease was published in the journalParkinsonism & Related Disorders. Dual-tasking (DT) measures an individuals ability to carry out a cognitive task (such as counting, or naming words that start with a particular letter) while engaging in a motor skill like walking Continue reading →

Posted in Parkinson's Treatment | Comments Off on Parkinson’s Patients Response to DBS May Depend on Years of Schooling – Parkinson’s News Today

FDA, FTC warn company marketing unapproved cannabidiol products with unsubstantiated claims to treat teething and ear pain in infants, autism, ADHD,…

Posted: Published on October 23rd, 2019

SILVER SPRING, Md., Oct. 22, 2019 /PRNewswire/ -- Today, the U.S. Continue reading →

Posted in Parkinson's Treatment | Comments Off on FDA, FTC warn company marketing unapproved cannabidiol products with unsubstantiated claims to treat teething and ear pain in infants, autism, ADHD,…

Things to Do in Miami: Night at the Market With Aaron Sanchez at Lincoln Eatery October 23, 2019 – Miami New Times

Posted: Published on October 23rd, 2019

Celebrity chef and Food Network star Aarn Snchez comes from a long line of strong women who have influenced his culinary career. Continue reading →

Posted in Parkinson's Treatment | Comments Off on Things to Do in Miami: Night at the Market With Aaron Sanchez at Lincoln Eatery October 23, 2019 – Miami New Times

‘A Journey Through Parkinson’s Disease’ Specialists host class to raise awareness of the disease – KTIV

Posted: Published on October 23rd, 2019

SOUTH SIOUX CITY, Nebraska (KTIV) Specialists say Parkinsons Disease is the second most common neurodegenerative disease worldwide. To raise awareness, the Iowa State Extension and Outreach taught a class about the disease on Monday. Specialists hosted A Journey Through Parkinsons Disease at the Norm Waitt YMCA, in South Sioux City, Nebraska Continue reading →

Posted in Parkinson's Treatment | Comments Off on ‘A Journey Through Parkinson’s Disease’ Specialists host class to raise awareness of the disease – KTIV

Page 1,316«..1020..1,3151,3161,3171,318..1,3301,340..»